Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Celularity ( (CELU) ) has provided an announcement.
Celularity Inc. held its Annual Meeting of Stockholders on December 19, 2025, where shareholders voted on director elections, auditor ratification and a proposed amendment to the company’s equity incentive plan. Stockholders reelected three Class I directors to serve until 2028 and ratified the appointment of EisnerAmper LLP as independent auditor for the 2025 fiscal year, but they rejected a proposal to increase the share reserve under the 2021 Equity Incentive Plan by 3.5 million shares, signaling shareholder resistance to further equity-based dilution and potentially constraining the company’s use of stock compensation going forward.
The most recent analyst rating on (CELU) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.
Spark’s Take on CELU Stock
According to Spark, TipRanks’ AI Analyst, CELU is a Underperform.
Celularity’s stock score is primarily impacted by its financial performance and technical analysis. The company faces significant financial challenges with high leverage and ongoing losses. Technical indicators suggest bearish momentum, and valuation metrics are unattractive due to negative earnings. The FDA warning adds regulatory risk, though it is not expected to have a material impact.
To see Spark’s full report on CELU stock, click here.
More about Celularity
Average Trading Volume: 114,768
Technical Sentiment Signal: Sell
Current Market Cap: $36.83M
See more data about CELU stock on TipRanks’ Stock Analysis page.